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Summary: We present a radiometric assay for the determination of urinary angiotensin-converting enzyme
activity, using benzoyl-[l-14C]glycyl-L-histidyl-L-leucine as the substrate. An optimal pH of 8.3, an optimal
chloride concentration of 0.375 mol/1 and complete inhibition by EDTA-Na2, captopril and enalaprilat confirm
the specificity of the assay. Comparison of dialysis and ultrafiltration for concentration of urine showed the
existence of angiotensin-converting enzyme inhibitors in human urine. Dialysis against water was the more
effective method for avoiding enzyme inhibition. After dialysis of urine, the assay was linear with time and
with enzyme concentration; it was highly sensitive (60 mU/1) and showed good reproducibility. Under our
technical conditions, we found angiotensin-converting enzyme activity in urine samples with quantitatively
abnormal protein contents, but not in normal urine. Urinary angiotensin-converting enzyme did not correlate
with proteinuria nor with water-salt parameters or creatinine. We confirm the kidney tubular epithelial origin
of the enzyme, and propose the use of our assay to study urinary angiotensin-converting enzyme as a marker
of renal tubular damage.
Introduction
Angiotensin I-converting enzyme is the peptidyldi-
peptide hydrolase (dipeptidylcarboxypeptidase EC
3.4.15.1) which cleaves angiotensin I to the potent
vasopressor angiotensin II and inactivates the vaso-
dilator bradykinin. Angiotensin-converting enzyme
activity is measurable in plasma and in most organs;
the enzyme is located on the luminal surface of the
endothelial cells as an ecto-glycoprotein (1).
The brush border of kidney tubules is one of the
extravascular sites richest in angiotensin-converting
activity (2). Because of this location some authors
have suggested the potential use of urinary angioten-
sin-converting activity as an index of renal tubular
damage (3, 4). Studies on urinary angiotensin-con-
verting enzyme are, however, rare, possibly because
its activity is low in urine and the accuracy of the
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present assays not proved; in particular, no criteria
of reliability have been specified (3 — 5). In addition,
mammalian urine may contain angiotensin-convert-
ing enzyme inhibitors (5).
In this study, we describe a sensitive and specific
radiometric assay for determination of urinary angio-
tensin-converting activity. We draw attention to the
presence of inhibitors of the enzyme in human urine,
and propose a prior dialysis of urine for an accurate
determination of the enzyme. Concentration of urine
before the measurement must be avoided.
Materials and Methods
Reagents
All reagents were of analytical grade. Potassium phosphates,
sodium chloride and ethyl acetate were from Merck (Darm-
stadt, FRG). EDTA-Na2 and 4-(2-hydroxyethyl)-l-piperazine-
ethanesulphonic acid (HEPES) were provided by Sigma Chem-
ical Co. (Saint Louis, Mo., USA). Benzoylglycyl-L-histidyl-L-
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leucine was from Calbiochem (San Diego, CaL, USA) and
benzoyl-[l-14C]glycyl-L-histidyl-L-leucine was purchased from
New England Nuclear (Boston, Ma., USA). Instafluor was from
Packard Instruments (Warrenville, 111., USA).
Captopril and enalaprilat were gifts from Squibb & Sons (Prin-
ceton, NJ., USA) and Merck Sharp & Dohme (West Point, Pa.,
USA), respectively. PM-10 (cut-off Mr 10000) and XM-50 (cut-
off Mr 50000) ultrafiltration membranes were from Amicon
Ltd. (Lexington, Ma., USA), dialysis membranes from Union
Carbide (Chicago, 111., USA) (cut-off Mr 1000).
Angio tens in-conver t ing enzymat ic assay
All urinary analyses were performed on 24-hour, fresh urine
containing no preservatives, which was centrifuged 10 min at
2000 g, +4°C. Extensive dialysis and concentration by ultra-
filtration were performed at 4- 4 °C with constant agitation on
10 ml aliquots of centrifuged urine.
The buffered substrate contained 0.165 mmol/1 radiolabelled
substrate and 2.175 mmol/1 cold substrate in 0.5 mol/1 potas-
sium phosphate — 0.75 mol/1 sodium chloride — pH = 8.3
buffer. Incubation was for one hour at 37 °C in 100 χ 8 mm
glass tubes, started by the addition of 25 μΐ of urine to 25 μΐ of
buffered substrate. The hydrolysis was stopped by the addition
of 50 μΐ HC1 1 mol/1. Benzoyl-[l-14C]glycine was then extracted
with 375 μΐ of ethyl acetate. After vigorous mixing and centrif-
ugation (10 min at 1000g, +4°C), 250 μΐ of the upper ethyl
acetate layer were directly dropped into 5 ml of Instafluor and
counted (Mini-Maxi-Tricarb Packard — Packard Instruments).
Angiotensin-converting enzyme activity was determined in du-
plicate and a blank was run with 0.15 mol/1 sodium chloride
replacing the urine.
Results are expressed as angiotensin-converting enzyme units
per litre of urine, one unit (U) corresponding to the release of
one μηιοί of benzoylglycine in one minute at 37 °C.
The formula used is derived from that described in 1. c. (6) after
calculation of the specific activity of the isotopic dilution (SA):
[Bq (dosage) - Bq (blank)]
' SA χ 0.91 χ 0.67 χ 60 χ 25 χ 10~6
_ ABq
~ SA χ 915 χ ΙΟ'6 '
where 0.91 is the benzoylglycine fraction extracted by ethyl
acetate; 0.67 is the counted organic fraction; 60 is time in
minutes and 25 χ 10~6 the volume of the sample in litres.
For example, with radiolabelled substrate of activity 88000
Bq/μιηοΐ, SA becomes 7000 Bq/μιηοΐ, thus
Other determinat ions
Proteinuria, creatininuria, urinary sodium (Na) and potassium
(K) were measured on the multiparametric discrete analysers
Greiner G300 (Langenthal, CH) and Astra 8 (Beckman Instru-
ments Inc. - Fullerton, Ca., USA).
Albumin/globulins ratio was determined with a Cliniscan den-
sitometer (Helena Laboratories — Beaumont, Te., USA) after
electrophoretic separation on agarose gel (Paragon SPE-II Kit,
Beckman).
Urines
Normal urines were from 15 apparently healthy people from
the laboratory staff (8 women, mean age 27.0 ± 10.8 years,
and 7 men, mean age 30.1 ±10.7 years) without any renal
disorder as judged by a normal diuresis and normal urinary
biological criteria: proteins < 0.15 g/1, Na = 131.1 ±49.0
mmol/1, K = 48.5 ± 15.8 mmol/1, creatinine = 12.2 ± 4.7
mmol/1.
Urines with an abnormally high protein content were selected
from 44 urinary samples sent to the laboratory for electropho-
retic analysis of quantitatively abnormal proteinuria (i.e.
>0.15g/day).
Data analys is
Results are expressed as mean ± standard deviation. Coeffi-
cients of variation (CVs) for reproducibility studies were ob-
tained from 20 determinations. Statistical comparisons were
performed with the non-parametric Mann-Whitney U-test.
Results
As we did not find any angiotensin-converting activity
in urines from normal subjects, we performed further
experiments on urines with high protein contents. A
direct determination showed the presence of angio-
tensin-converting activity in 16 of the 44 urine samples
tested. Concentration of these urines by ultrafiltration
on Amicon PM-10 did not increase angiotensin-con-
verting activity, but 24-hour dialysis against pure
water increased the enzymatic activity by 85 ± 42%.
Dialysis against water was more effective than dialysis
against the phosphate buffer of the enzymatic assay,
or against 0.375 mol/1 sodium chloride, or a 25 mmol/1
HEPES - 0.375 mol/1 NaCl - pH = 8.3 buffer.
Concentration of the dialysates on Amicon PM-10
never increased the enzymic activity, and more often
led to a substantial loss of activity. Dialysis against
water did not reveal any angiotensin-converting ac-
tivity in the other 28 urines with a high protein content
or in the normal urines. For the experiments reported
below, all urines were dialysed for 24 hours against
pure water. Under these conditions we determined the
main analytical parameters of the radiochemical as-
say.
The specificity was assessed by
(i) an optimal pH of 8.3 (fig. 1 b) and activation by
an increase in the chloride concentration (fig. 1 a),
both of which are characteristic of angiotensin-con-
verting enzyme activity determined with benzoylgly-
cine-histidyl-leucine as the substrate;
(ii) a complete inhibition of urinary angiotensin-con-
verting activity by 60 mmol/1 EDTA-Na2 (angioten-
sin-converting enzyme is a zinc metallopeptidase) and
100 μηιοΐ/ΐ captopril or 40 μηιοΐ/l enalaprilat (two
specific synthetic inhibitors of the enzyme). As phos-
phates have been implicated as inhibitors of angio-
tensin-converting activity, we verified that the con-
centration used (250 mmol/1) was not inhibitory. In
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Fig. 1. Urinary angiotensin-converting enzyme activity; pH
and Chloride activation curves. Each point is the mean
of three determinations of a pool of urinary samples
dialysed against water.
particular, substitution of the phosphate buffer by a
50 mmol/1 HEPES - 0.75 mol/1 NaCl - pH = 8.3
buffer did not increase the urinary angiotensin-con-
verting activity.
The assay was linear as a function of enzyme concen-
tration up to 4.0 U/l and as a function of time up to
120 minutes (fig. 2). When the urines were not dia-
lysed, the activity curves fell rapidly, suggesting an
inhibitory agent in the urines which can be eliminated
by dialysis (not shown). When, after dialysis, the
urines were concentrated on PM-10, the activity curve
swiftly decreased but not when a XM-50 membrane
was used instead of the PM-10 membrane (fig. 2a).
These data suggest the existence of a second inhibitory
substance in human urines eliminated neither by di-
alysis nor by ultrafiltration on PM-10 membrane, but
excluded by ultrafiltration on XM-50.
The sensitivity of the assay was determined by meas-
uring the radioactivity of 30 blanks in the same set
of experiments; the precision of the counts corre-
sponded to an assay sensitivity of 44 mU/1. Linear
dilution of urines, previously dialysed against water,
showed the limit of detection to be 66 mU/1 (fig. 2b).
Within-day reproducibility CVs were less than 1% for
two pools of urines with activities of 1.44 U/l and
3.21 U/l. Their between-days CVs were 10.3 and 4.4%
respectively. CVs were between 10 and 20% for a
urine pool containing 124 mU/1 angiotensin-convert-
ing activity.
In the 16 urines containing angiotensin-converting
activity the mean activity was 2.6 ± 4.7 U/l with a
range of 0.1 to 14.5 U/l and a median value of 440
mU/1, but the distribution of the values was not
unimodal. There was no apparent difference between
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Fig. 2. Radioassay of angiotensin-converting enzyme in urines,
showing activity with time (a), and linearity (b). Each
point is the mean of three determinations of a pool of
urinary samples, dialysed only (·) or concentrated on
Amicon PM-10 after dialysis (*).
6.7 ±15.1 g/1 (range: 0.35-62.4 g/1). Urinary angi-
otensin-converting activity did not correlate with pro-
teinuria (fig. 3), or with the albumin/globulins ratio
(1.79 ± 1.06), or with any kind of abnormality on
the agarose electrophoresis pattern, such as a peak in







Fig. 3. Lack of correlation (r = 0.29) between angiotensin-
converting activity and proteinuria measured in 16 urine
samples with detectable enzyme activity.
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Angiotensin-converting activity in urines was not re-
lated to water-salt excretion; thus, no statistical link
appeared between the enzyme activity and urinary Na
(39.7 ± 35.1 mmol/1), K (34.0 ± 13.9 mmol/1), or
Na/K (1.45 ± 1.49). Moreover, angiotensin-convert-
ing activity was not linked to creatininuria (8.16
± 7.05 mmol/1). These data were the same when
enzyme activity was expressed as U/g of protein or
as U/mmol of creatinine.
Discussion
We modified the radiometric method of Rohrbach (6)
for the determination of urinary angiotensin-convert-
ing enzyme activity. Dilution of the radiolabelled sub-
strate, benzoyl-[l -14C]glycyl-L-histidyl-L-leucine, with
cold substrate gives a sensitivity suitable for a direct
determination on urine samples, i.e. without prior
concentration.
Dialysis of the urines is necessary to eliminate at least
one inhibitor, which, as previously suspected (5), is of
low molecular weight. According to the results ob-
tained with PM-10 and XM-50 ultrafiltration mem-
branes, another inhibitor may also be present; this
inhibitor, relative molecular mass 10000 — 50000, is
less inhibitory than the dialysable inhibitor since we
could not reveal its inhibitory effect on non-concen-
trated urines. Some ions and metals have been impli-
cated as physiological angiotensin-converting enzyme
inhibitors (5, 7); Lieberman described inhibition by
human plasma but did not identify the agent respon-
sible (8). Hazato & Kase found an inhibitor in pig
plasma and identified it as an oligopeptide (9). Such
low molecular weight inhibitors have been detected
also in urine. Potential physiological inhibitors of
higher molecular weight have also been reported, i. e.
albumin and some of its fragments (10), or fibrinogen
fragments (11). In our study, it was difficult to cor-
relate the inhibitory power of the urines with their
protein concentration because we had only a few
samples with both low angiotensin-converting activity
and high protein content. Further investigations are
necessary to characterize these urinary inhibitors of
angiotensin-converting enzyme activity.
The reliability of our radiochemical enzyme assay
after dialysis of urines is assessed by its specificity,
linearity and reproducibility. The sensitivity is higher
than that of most the methods described for the
determination of angiotensin-converting activity in
plasma. Only fluorimetric assays attain this sensitivity
(12), but radioassays avoid the interferences fre-
quently encountered with fluorimetric as well as pho-
tometric methods (13). Kokubu et al. (14) adapted
Cushmarfs spectrophotometric assay (13) to urines
but their method involves partial purification of the
enzyme from the urine. Pitotti et al. (15) described a
HPLC method but, once again, with difficult pretreat-
ment of the urinary samples, and with no indication
of the reliability or precision. A colorimetric assay
was also proposed but without evidence of specificity
for angiotensin-converting enzyme (3). Ryan et al. (5),
like the present authors (personal data), were unable
to adapt Cushman's assay for the determination of
angiotensin-converting activity in mammalian urines,
since the latter contain high concentrations of pig-
ments. On the other hand, the radiochemical assay of
Rohrbach (6) has poor sensitivity, detecting 500 mU/1,
which is about 10-fold the limit of detection of our
assay; thus Rohrbach's assay cannot be directly
adapted to urine determination.
Under our technical conditions we could not detect
angiotensin-converting activity in the urines of normal
subjects, but we were able to measure the enzyme
activity in urines with a quantitatively abnormal pro-
tein content. Some authors (14,15) found angiotensin-
converting activity in normal, 24-hour urines; possibly
they were measuring the physiological replacement of
the renal tubular brush-border whose epithelial cells
are sedimentable. In view of the high specific angio-
tensin-converting activities in the male genital tract
(16, 17), a gonadic or prostatic origin of urinary
angiotensin-converting enzyme might have been ex-
pected, but we found no difference between males and
females; in particular, normal men did not excrete
angiotensin-converting activity in the urine. The ab-
sence of a correlation between this urinary enzymatic
activity and proteinuria, and even more the lack of
dependence of this activity on the indices of glomer-
ular function, such as creatininuria or albuminuria,
eliminate the possibility of a passage of the plasmatic
enzyme throughout the glomerular filter. Damage of
renal glomeruli cannot explain a significant enzymu-
ria, since glomerular epithelial and endothelial cells
contain only a little angiotensin-converting enzyme
(18, 19). Thus, in agreement with other authors (3,
4), we conclude that urinary angiotensin-converting
enzyme is of tubular origin, as in the case of most
enzymurias (20). We also showed that urinary angio-
tensin-converting enzyme excretion is independent of
sodium and potassium excretion, so that physiological
or pathological variations of this enzyme in response
to haemodynamic or dietary factors would not be
expected.
Our specific, sensitive and reproducible radioassay
might enable the comparison of angiotensin-convert-
ing enzyme with other materials of tubular origin for
their suitability as specific, early and precise markers
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of tubular damage during renal disorders. The assay
will also be of use in investigating putative inhibitors
of angiotensin-converting enzyme in mammalian bi-
ological fluids.
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